Millennium Management LLC Lowers Position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Millennium Management LLC reduced its stake in shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Free Report) by 94.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,133 shares of the biotechnology company's stock after selling 165,920 shares during the quarter. Millennium Management LLC owned approximately 0.18% of Atara Biotherapeutics worth $135,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Bank of America Corp DE increased its holdings in Atara Biotherapeutics by 0.8% in the 4th quarter. Bank of America Corp DE now owns 205,170 shares of the biotechnology company's stock worth $2,731,000 after buying an additional 1,543 shares during the period. Citadel Advisors LLC increased its holdings in Atara Biotherapeutics by 2.6% in the 4th quarter. Citadel Advisors LLC now owns 267,353 shares of the biotechnology company's stock worth $3,558,000 after buying an additional 6,873 shares during the period. Geode Capital Management LLC increased its holdings in Atara Biotherapeutics by 17.2% in the 4th quarter. Geode Capital Management LLC now owns 54,744 shares of the biotechnology company's stock worth $729,000 after buying an additional 8,024 shares during the period. Staley Capital Advisers Inc. increased its holdings in Atara Biotherapeutics by 25.0% in the 4th quarter. Staley Capital Advisers Inc. now owns 50,000 shares of the biotechnology company's stock worth $666,000 after buying an additional 10,000 shares during the period. Finally, Northern Trust Corp acquired a new position in Atara Biotherapeutics in the 4th quarter worth approximately $149,000. 70.90% of the stock is owned by hedge funds and other institutional investors.

Atara Biotherapeutics Stock Down 2.7%

Shares of ATRA stock traded down $0.24 during trading hours on Monday, hitting $8.58. 39,430 shares of the company's stock were exchanged, compared to its average volume of 125,998. The firm has a market cap of $51.15 million, a P/E ratio of -0.33 and a beta of 0.19. The firm has a 50 day moving average of $7.31 and a two-hundred day moving average of $8.67. Atara Biotherapeutics, Inc. has a fifty-two week low of $5.01 and a fifty-two week high of $18.71.

Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The biotechnology company reported $3.50 EPS for the quarter, beating the consensus estimate of ($3.07) by $6.57. The firm had revenue of $98.10 million during the quarter, compared to analyst estimates of $4.30 million. On average, equities analysts forecast that Atara Biotherapeutics, Inc. will post -10.39 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group reiterated a "buy" rating and issued a $17.00 price target on shares of Atara Biotherapeutics in a report on Tuesday, March 11th. One analyst has rated the stock with a sell rating, three have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $17.75.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.